{"id":"rimegepant-75mg-every-other-day-dosing","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"P-glycoprotein inhibitors (e.g., cyclosporine, ketoconazole)","action":"Avoid","effect":"Increased rimegepant exposure"},{"drug":"P-glycoprotein inducers (e.g., rifampin, St. John's Wort)","action":"Avoid","effect":"Decreased rimegepant exposure"},{"drug":"Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin)","action":"Avoid","effect":"Increased rimegepant exposure"},{"drug":"Strong CYP3A4 inducers (e.g., rifampin, St. John's Wort)","action":"Avoid","effect":"Decreased rimegepant exposure"},{"drug":"CYP3A4 substrates (e.g., midazolam, simvastatin)","action":"Monitor","effect":"Increased exposure to CYP3A4 substrates"}],"commonSideEffects":[{"effect":"Nasopharyngitis","drugRate":"5.6%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":232,"totalAffected":13,"trialsReporting":1},{"effect":"COVID-19","drugRate":"0.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":232,"totalAffected":0,"trialsReporting":1}],"contraindications":["Hypersensitivity to rimegepant or any component of Nurtec; severe hepatic impairment; concomitant use of strong inhibitors of CYP3A4 and strong inducers of CYP3A4; concomitant use of p-glycoprotein (P-gp) inhibitors and strong P-gp inducers."],"specialPopulations":{"Pregnancy":"There is no information available about the use of rimegepant in pregnant women.","Geriatric use":"Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of rimegepant in the elderly.","Paediatric use":"Safety and efficacy have not been established in children.","Renal impairment":"Use is not recommended in patients with end-stage kidney disease.","Hepatic impairment":"Use is not recommended in patients with severe liver disease."},"seriousAdverseEvents":[{"event":"Crohn's disease","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"0.4%"},{"event":"Oesophageal carcinoma","detail":"Neoplasms benign, malignant and unspecified (incl cysts and polyps). 1 trial(s).","severity":"serious","incidence":"0.4%"},{"event":"Status migrainosus","detail":"Nervous system disorders. 1 trial(s).","severity":"serious","incidence":"0.4%"},{"event":"Appendicitis","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Infected cyst","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Pneumonia","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Urinary tract infection","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Post procedural haemorrhage","detail":"Injury, poisoning and procedural complications. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Liver function test abnormal","detail":"Investigations. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Back pain","detail":"Musculoskeletal and connective tissue disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Costochondritis","detail":"Musculoskeletal and connective tissue disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"}]},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"patents":{"url":"","method":"deterministic","source":"FDA Orange Book + Purple Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T22:29:35.425139+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T22:29:45.605983+00:00"},"chemblData":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2364629/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T22:29:28.805859+00:00"},"trialDetails":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (1 trials with endpoints)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T22:29:46.994244+00:00"},"publicationCount":{"url":"","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T22:29:27.131527+00:00"},"participantFlowData":{"url":"","method":"deterministic","source":"ClinicalTrials.gov participantFlowModule","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T22:29:46.994239+00:00"},"structuredTrialResults":{"url":"","method":"deterministic","source":"ClinicalTrials.gov resultsSection (1 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T22:29:46.994232+00:00"},"commercial.annualRevenue":{"url":"","method":"deterministic","source":"SEC EDGAR 10-K","rawText":"$798M FY2025","confidence":0.8,"sourceType":"sec_edgar","retrievedAt":"2026-04-19T22:29:35.425173+00:00"},"safety.commonSideEffects":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (1 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-20T08:35:32.729021+00:00"},"safety.seriousAdverseEvents":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (1 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T22:29:46.994009+00:00"}},"allNames":"rimegepant 75mg every other day dosing","offLabel":[],"timeline":[],"aiSummary":"Rimegepant, a 75mg every other day dosing drug developed by Pfizer, holds a significant market position with $798M in revenue, making it one of the leading treatments for migraines. Despite its strong market presence, Rimegepant faces competition from drugs like Candesartan, Telmisartan, Erenumab, Fremanezumab, and Galcanezumab, which have stronger guideline support for episodic migraine prevention. A key risk for Rimegepant is the lack of ongoing clinical trials, which may limit future evidence and regulatory support. The pipeline outlook remains uncertain due to the absence of new clinical trials and the requirement for a PD-L1 companion diagnostic for several indications.","brandName":"Rimegepant 75mg every other day dosing","ecosystem":[],"isGeneric":true,"mechanism":{"target":"calcitonin gene-related peptide receptor","novelty":"first-in-class","modality":"small molecule","drugClass":"calcitonin gene-related peptide receptor antagonist","explanation":"Rimegepant works by binding to the calcitonin gene-related peptide receptor, which is involved in the pathophysiology of migraines. This binding action helps to reduce the frequency and severity of migraine attacks. By targeting this specific receptor, rimegepant offers a unique approach to treating migraines compared to other medications.","oneSentence":"Rimegepant targets the calcitonin gene-related peptide receptor to treat migraines.","technicalDetail":"Rimegepant is a calcitonin gene-related peptide receptor antagonist, which means it blocks the action of calcitonin gene-related peptide at its receptor. This blockade reduces the release of pro-inflammatory neuropeptides, leading to decreased migraine frequency and severity. Rimegepant's mechanism of action is distinct from other migraine treatments, which often target different pathways or receptors."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"chemblData":{"prodrug":0,"chemblId":"CHEMBL2364629","maxPhase":"4.0","chirality":1,"parenteral":false,"availability":1,"moleculeType":"Small molecule","withdrawnFlag":false,"naturalProduct":0,"blackBoxWarning":0,"oralBioavailable":true},"commercial":{"revenueYear":2025,"annualCostUS":"$2,869","annualRevenue":798,"genericStatus":"Generic — off-patent","revenueSource":"SEC 8-K Bristol-Myers Squibb (2026-02-05)","currentRevenue":"$5,353 million","revenueCurrency":"USD","peakSalesEstimate":"$5,353 million","revenueConfidence":"verified (SEC filing)","revenueExtractedAt":"2026-04-01T11:47:02.606798","revenueExtractedBy":"revenue-sec"},"fdaRecalls":[],"references":[{"id":1,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=rimegepant-75mg-every-other-day-dosing","fields":["publications"],"source":"PubMed/NCBI"},{"id":2,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":3,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":4,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":4,"lastValidatedAt":"2026-04-20T08:35:45.746304+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Candesartan","company":"Not specified","advantage":"Stronger guideline support for episodic migraine prevention"},{"name":"Telmisartan","company":"Not specified","advantage":"Stronger guideline support for episodic migraine prevention"},{"name":"Erenumab","company":"Not specified","advantage":"Stronger guideline support for episodic migraine prevention"},{"name":"Fremanezumab","company":"Not specified","advantage":"Stronger guideline support for episodic migraine prevention"},{"name":"Galcanezumab","company":"Not specified","advantage":"Stronger guideline support for episodic migraine prevention"}],"genericName":"rimegepant-75mg-every-other-day-dosing","indications":{"approved":[{"name":"Acute treatment of migraine attacks with or without aura in adults","regulator":"FDA"},{"name":"Prevention of migraine attacks in adults","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05217927","phase":"PHASE4","title":"Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens","status":"","acronym":null,"sponsor":"Pfizer","isPivotal":false,"primaryCI":"[-1.22, -0.01]","primaryHR":"-0.6","enrollment":1415,"indication":"Migraine","endpointCount":20,"primaryPValue":"=0.0220","completionDate":"","primaryEndpoint":"Mean Change From Observation Phase (OP) in the Number of Migraine Days Per Month Over Entire DBT Phase (Weeks 1 to 12)"}],"_emaApprovals":[{"date":"","name":"Rimegepant 75mg every other day dosing","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":true,"chemblId":"CHEMBL2364629","moleculeType":"Small molecule","molecularWeight":"1221.26"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL2364629"},"formularyStatus":[],"_offLabelChecked":true,"chemblMechanisms":[{"actionType":"ANTAGONIST","targetChemblId":"CHEMBL3798","mechanismComment":"Therapeutic mechanism not fully elucidated.","mechanismOfAction":"Calcitonin gene-related peptide type 1 receptor antagonist"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Neuroscience"],"_revenueScrapedAt":"2026-04-01 10:47:02.629581+00","biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"participantFlowData":[{"nctId":"NCT05217927","groups":[{"id":"FG000","title":"Double Blind (DB) Rimegepant/ Placebo/ Open Label (OL) Rimegepant","description":"Participants received rimegepant (RMG) 75 mg, orally disintegrating tablets (ODT), once every other day (EOD) alternating with matching placebo dosed EOD for 12 weeks in the double blind treatment (DB"},{"id":"FG001","title":"DB Rimegepant/OL Rimegepant","description":"Participants received RMG 75 mg ODT, once daily for 12 weeks in the DBT phase. Eligible participants continued to receive RMG 75 mg ODT once daily for 12 weeks in the OLE phase. Participants were foll"},{"id":"FG002","title":"DB Placebo/OL Rimegepant","description":"Participants received matching placebo for RMG 75 mg ODT once daily for 12 weeks, in the DBT phase. Eligible participants received RMG 75 mg ODT once daily for 12 weeks in the OLE phase. Participants "}],"acronym":null,"periods":[{"title":"DBT Phase","milestones":[{"type":"STARTED","counts":{"FG000":"234","FG001":"232","FG002":"233"}},{"type":"Treated","counts":{"FG000":"232","FG001":"229","FG002":"231"}},{"type":"COMPLETED","counts":{"FG000":"204","FG001":"209","FG002":"208"}},{"type":"NOT COMPLETED","counts":{"FG000":"30","FG001":"23","FG002":"25"}}],"dropWithdraws":[{"type":"Adverse Event","counts":{"FG000":"7","FG001":"2","FG002":"5"}},{"type":"Lack of Efficacy","counts":{"FG000":"1","FG001":"0","FG002":"0"}},{"type":"Lost to Follow-up","counts":{"FG000":"0","FG001":"2","FG002":"0"}},{"type":"Non-compliance","counts":{"FG000":"1","FG001":"0","FG002":"0"}},{"type":"Pregnancy","counts":{"FG000":"0","FG001":"0","FG002":"1"}},{"type":"Protocol Violation","counts":{"FG000":"0","FG001":"2","FG002":"1"}},{"type":"Protocol-specified withdrawal criterion met","counts":{"FG000":"4","FG001":"6","FG002":"5"}},{"type":"Withdrawal of consent","counts":{"FG000":"8","FG001":"5","FG002":"7"}},{"type":"Other","counts":{"FG000":"7","FG001":"3","FG002":"4"}},{"type":"Randomized, not treated","counts":{"FG000":"2","FG001":"3","FG002":"2"}}]},{"title":"OLE Phase","milestones":[{"type":"STARTED","counts":{"FG000":"182","FG001":"196","FG002":"195"}},{"type":"COMPLETED","counts":{"FG000":"170","FG001":"187","FG002":"183"}},{"type":"NOT COMPLETED","counts":{"FG000":"12","FG001":"9","FG002":"12"}}],"dropWithdraws":[{"type":"Adverse Event","counts":{"FG000":"4","FG001":"1","FG002":"1"}},{"type":"Extension phase eligibility failure","counts":{"FG000":"1","FG001":"0","FG002":"0"}},{"type":"Lost to Follow-up","counts":{"FG000":"1","FG001":"2","FG002":"1"}},{"type":"Non-compliance","counts":{"FG000":"0","FG001":"0","FG002":"1"}},{"type":"Other","counts":{"FG000":"3","FG001":"5","FG002":"4"}},{"type":"Withdrawal of consent","counts":{"FG000":"3","FG001":"1","FG002":"5"}}]}],"recruitment":"","preAssignment":"A total of 1415 participants were enrolled in the study, of which 716 failed screening and 699 participants were randomized. Of the 699 randomized participants, 692 participants received the study intervention."}],"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"structuredTrialResults":[{"hr":"-0.6","nctId":"NCT05217927","phase":"PHASE4","pValue":"=0.0220","ciLower":"-1.22","ciUpper":"-0.01","endpoint":"Mean Change From Observation Phase (OP) in the Number of Migraine Days Per Month Over Entire DBT Phase (Weeks 1 to 12)","enrollment":1415}],"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"small molecule","firstApprovalDate":"","enrichmentLevel":5,"visitCount":10,"regulatoryByCountry":[{"country_code":"AU","regulator":"TGA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"CH","regulator":"Swissmedic","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"NO","regulator":"NoMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"IS","regulator":"IMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"NZ","regulator":"Medsafe","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"AT","regulator":"AGES","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"BE","regulator":"FAMHP","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"BG","regulator":"BDA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"HR","regulator":"HALMED","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"CY","regulator":"PHS","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"CZ","regulator":"SUKL","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"DK","regulator":"DKMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"EE","regulator":"SAM","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"FI","regulator":"Fimea","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"FR","regulator":"ANSM","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"DE","regulator":"BfArM","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"GR","regulator":"EOF","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"HU","regulator":"OGYEI","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"IE","regulator":"HPRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"IT","regulator":"AIFA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"LV","regulator":"ZVA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"LT","regulator":"VVKT","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"LU","regulator":"MS","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"MT","regulator":"MMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"NL","regulator":"MEB","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"PL","regulator":"URPL","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"PT","regulator":"Infarmed","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"RO","regulator":"ANMDMR","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"SK","regulator":"SIDC","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"SI","regulator":"JAZMP","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"ES","regulator":"AEMPS","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"SE","regulator":"MPA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"2869.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":4,"lastValidatedAt":"2026-04-20T08:35:45.746304+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}